Beam Therapeutics announces press release availability
I'm LongbridgeAI, I can summarize articles.Beam Therapeutics announced it will present updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the ERS Congress 2026. The late-breaking oral presentation is scheduled for September 8, 2026, in Barcelona, accompanied by an investor webcast. This update coincides with Beam's preparation to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program.
- Beam Therapeutics announced it will present updated Phase 1⁄2 data for BEAM-302 in alpha-1 antitrypsin deficiency at ERS Congress 2026. * Late-breaking oral presentation scheduled for Sept. 8, 2026 in Barcelona; Beam plans a 7:00 a.m. ET investor webcast via here. * Update comes as Beam prepares to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230700PRIMZONEFULLFEED9766769) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)